Evidence map›Paper›PMID 41508034›Full record

ArticleJournal of nanobiotechnology2026

Unraveling the structure-activity relationship of alloying in nanozyme design for synergistic tumor metabolic-immunotherapy.

Chaoran Liu, Wenyu Zhang, Qingbin He, Xinyu Ma, Jianfeng Qiu, Runxiao Zheng, Hongjin Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chaoran Liu *The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, P. R. China.
Wenyu Zhang *The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, P. R. China.
Qingbin HeMedical Engineering and Technology Research Center, School of Radiology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, P. R. China.
Xinyu MaMedical Engineering and Technology Research Center, School of Radiology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, P. R. China.
Jianfeng QiuMedical Engineering and Technology Research Center, School of Radiology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, P. R. China.
Runxiao ZhengThe First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, P. R. China. zhengrunxiao@sdfmu.edu.cn.
Hongjin XueThe First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, P. R. China. hjxue188@163.com.

Funding

National Natural Science Foundation of China 22207066Natural Science Foundation of Shandong Province ZR2025QC959
6 · The paper itself

Abstract

Catalyzing the glucose cascade reaction to impair tumor cell energy metabolism represents a promising strategy for tumor therapy. However, the application of natural enzymes as therapeutic agents remains limited by various challenges. Although nanozymes with multi-enzyme activities, including glucose oxidase-like (GOx-like) activity, have been reported, their development often involves complex material combinations and cumbersome synthesis processes. Here, we develop a nanozyme with GOx-, peroxidase (POD)-, superoxide dismutase (SOD)-, and NADH oxidase (NOX)-mimic activities by simply controlling the AuPt alloy ratio. The optimal cascade activity was observed for the nanozyme at an Au: Pt proportion of 13:7. Density functional theory (DFT) calculations revealed that Au sites drive glucose dehydrogenation (GOx-like), while Pt sites facilitate hydroxyl radical (•OH) generation (POD-like). Both in vitro and in vivo data indicated that Au

Indexed as

AlloysImmunotherapyNeoplasmsAnimalsAntineoplastic AgentsApoptosisCell Line, TumorFemaleGlucoseGlucose OxidaseGoldHumansHydroxyl RadicalMiceMultienzyme ComplexesNADH, NADPH OxidoreductasesAlloysAntineoplastic AgentsGlucoseGlucose OxidaseGoldHydroxyl RadicalMultienzyme ComplexesNADH, NADPH OxidoreductasesNADH oxidasePeroxidasePlatinumSuperoxide DismutaseAlloy nanozymesAntitumorMetabolism homeostasisSynergistic therapy

Identifiers

PMID41508034
PMCPMC12882607

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.